TriangleDISEASE & TREATMENT SETTING
TECENTRIQ: Bladder Cancer (adjuvant) after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.6 Muscle Invasive Bladder Cancer TECENTRIQ, as a single agent, is indicated as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
Broader topic: Bladder Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- adjuvant
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD)
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for TECENTRIQ (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.6 Muscle Invasive Bladder Cancer TECENTRIQ, as a single agent, is indicated as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice